share_log

Resonate Blends Executes a Share Exchange Agreement With Emergent Health Corp.

Resonate Blends Executes a Share Exchange Agreement With Emergent Health Corp.

Resonate Blends 与 Emergent Health Corp. 签署股票交换协议
Accesswire ·  03/15 11:20

NORTH BERGEN, NJ / ACCESSWIRE / March 15, 2024 / Resonate Blends, Inc. (OTCQB:KOAN) ("Resonate Blends" or the "Company") is pleased to report it has completed a Share Exchange Agreement with the holders of certain preferred stock of Emergent Health Corp. (OTC Pink:EMGE) ("Emergent Health" or "EMGE") (The "Agreement"), with the closing having taken place on March 14, 2024. Resonate Blends, the parent company, will become known as Apollo Biowellness, Inc. ("Apollo Biowellness"). The company is now located at One Marine Plaza, Suite 305A, North Bergen, NJ 04047.

新泽西州北卑尔根/ACCESSWIRE/2024年3月15日/Resonate Blends, Inc.(OTCQB: KOAN)(“Resonate Blends” 或 “公司”)欣然报告说,它已与Emergent Health Corp.(场外交易链接:EMGE)(“Emergent Health” 或 “EMGE”)的某些优先股(“协议”)的持有人完成了股票交换协议,收盘时已结束于 2024 年 3 月 14 日举行。母公司Resonate Blends将更名为阿波罗生物健康有限公司(“阿波罗生物健康”)。该公司现在位于新泽西州北卑尔根海洋广场一号305A套房 04047。

The Company (to be known as Apollo Biowellness) is a holding company focused on regenerative medicine sold primarily to doctor's offices and clinics, as well as the public. The Company now consists of the following subsidiaries: Evolutionary Biologics, Integrative Practice Solutions LLC and Juventix Regenerative Medical LLC, and soon-to-be-launched Maximus Mean's Health.

该公司(更名为Apollo Biowellness)是一家控股公司,专注于再生医学,主要销售给医生办公室和诊所以及公众。该公司现在由以下子公司组成:Evolutionary Biologics、Integrative Practice Solutions LLC和Juventix Regenerative Medical LLC以及即将成立的Maximus Mean's Health。

The Company, as Apollo Biowellness, is a synergistic ecosystem of companies disrupting the next generation of the $5.6 trillion Global Health & Wellness Market. The global regenerative medicine market is currently at $20.04 billion in 2021 and predicted to be worth around $125.54 billion by 2030. We offer a one-stop solution for regenerative medicine with superior proprietary products and processes focused on the $1.1 trillion Personal Care, Beauty and Anti-Aging markets, with products sold through professional offices and directly to consumers. Our offerings include skin care, wound care, cosmetics, regenerative aesthetics, hair growth, ED, longevity/anti-aging, osteoarthritis and more. We foresee significant growth once we open DTC and OTC markets with FDA approval, which we will apply for, for skin care and hair growth products using human exosomes. We currently have a professional sales force with 700+ independent sales reps and distribution partners covering all aspects of our brand ecosystem. The company's subsidiaries will benefit from synergies in all backroom disciplines as well as sales & marketing and a seasoned collaborative management team.

该公司名为Apollo Biowellness,是一个由公司组成的协同生态系统,正在颠覆下一代5.6万亿美元的全球健康与保健市场。2021年,全球再生医学市场目前为200.4亿美元,预计到2030年将达到约1255.4亿美元。我们为再生医学提供一站式解决方案,提供卓越的专有产品和工艺,专注于1.1万亿美元的个人护理、美容和抗衰老市场,产品通过专业办公室直接销售给消费者。我们的产品包括皮肤护理、伤口护理、化妆品、再生美学、头发生长、ED、长寿/抗衰老、骨关节炎等。我们预计,一旦我们在获得美国食品药品管理局批准的情况下开放DTC和OTC市场,使用人类外泌体的护肤和头发生长产品将获得美国食品药品管理局的批准,我们将申请该批准。我们目前拥有一支专业的销售队伍,拥有700多名独立销售代表和分销合作伙伴,涵盖我们品牌生态系统的各个方面。该公司的子公司将受益于所有幕后领域以及销售和营销以及经验丰富的协作管理团队的协同效应。

Emergent Health Corp. will continue with the operations of Wholistic Brands, a majority-controlled subsidiary as a separate, but affiliated entity of the Parent Company, it is a brand that represents the best natural formulas made from plant-based ingredients, including shelf-stable plant-based exosomes. Wholistic is developing products in support of our suite of businesses while building a proprietary D2C and consumer business around clean wholistic health.

Emergent Health Corp. 将继续经营Wholistic Brands的运营。Wholistic Brands是母公司控股的子公司,是母公司的一个独立但附属的实体,该品牌代表了由植物性成分制成的最佳天然配方,包括可保质期的植物性外泌体。Wholistic正在开发支持我们的业务套件的产品,同时围绕清洁整体健康建立专有的D2C和消费者业务。

As part of the Agreement, Jim Morrison is the new Chairman of the Board of Directors and President/CEO of the Company. Morrison has stepped down as CEO/President of Emergent Health Corp. but will continue as Chairman of the Board of Directors of Emergent. The new management of Emergent will also be appointed and will report to the Board of the Company.

作为协议的一部分,吉姆·莫里森是公司新任董事会主席兼总裁/首席执行官。莫里森已辞去Emergent Health Corp首席执行官/总裁的职务,但将继续担任Emergent董事会主席。还将任命Emergent的新管理层,并将向公司董事会报告。

Jim Morrison is considered by many to be one of the leading personal care strategists in the world, as well as one of the top executives. Morrison was Chairman and President/CEO of Emergent Health Corp., a dynamic company in the wellness and regenerative biologics space. He has most recently been CEO of StarShop, which was the first celebrity-driven video shopping app, that was launched in partnership with SPRINT. His track record of leadership and accomplishment in the personal care products space has been unparalleled. Morrison was President of L'Oreal for over nine years. He was responsible for many acquisitions, including both Redken and Matrix, and top-line growth that averaged over 20% during his tenure. Prior to L'Oreal, Morrison was President and CEO of Graham Webb, one of the most successful startups in the hair care space. After leaving L'Oreal Morrison was CEO and owner of Sexy Hair Concepts for four years. In 2006, Business Week Magazine wrote, "Over the last two decades, Mr. Morrison has had a profound impact on the American Beauty Industry. In the industry's history no other executive has had the level of financial responsibility or breadth of organizational experience as Jim. His devotion to, and success within the industry is unmatched."

许多人认为吉姆·莫里森是全球领先的个人护理策略师之一,也是高层管理人员之一。莫里森曾是Emergent Health Corp. 的董事长兼总裁兼首席执行官,该公司是一家在健康和再生生物制剂领域充满活力的公司。他最近担任StarShop的首席执行官,这是第一款由名人驱动的视频购物应用程序,是与SPRINT合作推出的。他在个人护理产品领域的领导和成就记录是无与伦比的。莫里森担任欧莱雅总裁超过九年。他负责许多收购,包括Redken和Matrix,以及在他任职期间平均超过20%的收入增长。在加入欧莱雅之前,莫里森曾担任格雷厄姆·韦伯的总裁兼首席执行官,格雷厄姆·韦伯是护发领域最成功的初创公司之一。离开欧莱雅后,莫里森曾担任Sexy Hair Concepts的首席执行官兼所有者四年。2006年,《商业周刊》杂志写道:“在过去的二十年中,莫里森先生对美国美容行业产生了深远的影响。在该行业的历史上,没有其他高管像吉姆那样具有财务责任水平或丰富的组织经验。他对该行业的热爱和成功是无与伦比的。”

As part of the transaction, the Company is conveying the previous assets of Resonate Blends to prior management.

作为交易的一部分,公司正在将Resonate Blends先前的资产移交给前任管理层。

About the former parent company Resonate Blends, Inc. (OTCQB:KOAN)

关于前母公司 Resonate Blends, Inc.(OTCQB: KOAN)

Resonate Blends is the former parent company, and as part of the transaction all the Intellectual Property and assets associated with it are being conveyed and transferred back to the former founding executive of Resonate Blends.

Resonate Blends是前母公司,作为交易的一部分,所有与之相关的知识产权和资产都将移交给Resonate Blends的前创始高管。

Apollo Biowellness is the new parent company and has no connection with the previous business of Resonate Blends.

Apollo Biowellness是新的母公司,与Resonate Blends之前的业务没有任何关系。

ABOUT EMERGENT HEALTH CORP./Apollo Biowellness, Inc. (OTCMarkets Pink EMGE)

关于紧急健康公司/Apollo Biowellness, Inc.(场外市场粉红EMGE)

Emergent Health curates, develops and sells products in the regenerative health space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through "Content Based Shopping" using "Influencers" to successfully position products throughout the United States and Internationally. Evolutionary Biologics is a new kind of biologics company founded for a clear purpose: bring cutting-edge regenerative products to the medical community. Emergent asserts that its products are not approved by the FDA to diagnose, treat, cure or prevent any disease(s). For more information, please visit Emergent's website.

Emergent Health 策划、开发和销售再生健康领域的产品。其产品包括可摄入物和外用药物,适合全家使用。该公司使用 “Influencers” 在线分销其产品,并通过 “基于内容的购物” 成功地在美国和国际上定位产品。Evolutionary Biologics是一家新型的生物制剂公司,其成立的目的很明确:为医学界带来尖端的再生产品。Emergent断言,其产品未经美国食品药品管理局批准用于诊断、治疗、治愈或预防任何疾病。欲了解更多信息,请访问Emergent的网站。

Before using any of our products, you should always consult with your veterinarian and/or family doctor.

在使用我们的任何产品之前,您应始终咨询您的兽医和/或家庭医生。

Forward-Looking Statements

前瞻性陈述

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.

本新闻稿可能包含1933年《证券法》第27A条和1934年《证券交易法》第21E条所指的 “前瞻性陈述”。此类陈述包括但不限于与我们的产品开发计划有关的任何陈述以及任何其他非历史事实的陈述。此类陈述涉及风险和不确定性,可能会对我们的业务、经营业绩、财务状况和股价产生负面影响。可能导致实际结果与管理层当前预期存在重大差异的因素包括与我们的筹资能力、监管批准程序、候选药物的开发、测试、生产和销售、专利和知识产权问题以及战略协议和关系相关的风险和不确定性。除非法律要求,否则我们明确表示不承担任何义务或承诺公开发布此处包含的任何前瞻性陈述的任何更新或修订,以反映我们预期的任何变化或任何此类陈述所依据的事件、条件或情况的任何变化。公司向美国证券交易委员会提交的最新10-K表年度报告中的 “风险因素” 中包含了对可能影响公司业务(包括其任何子公司业务)的风险和不确定性的完整讨论。

Corporate Contact:

公司联系人:

Jim Morrison
CEO/Director
jmorrison@evolutionarybiologics.com
203-253-9191

吉姆·莫里森
首席执行官/总监
jmorrison@evolutionarybiologics.com
203-253-9191

Contact Information:

联系信息:

Jim Morrison
President/CEO
jmorrison@evolutionarybiologics.com
2032539191

吉姆·莫里森
总裁/首席执行官
jmorrison@evolutionarybiologics.com
2032539191

Jim Zimbler
President, Emergent Health
jzimbler@emergenthealthcompany.com
6318061420

吉姆·齐姆布勒
紧急健康总裁
jzimbler@emergenthealthcompany.com
6318061420

SOURCE: Resonate Blends, Inc.

来源:Resonate Blends, Inc.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发